Skip to main content

Home/ Business News/ Group items tagged REPCF

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Equities Group

RepliCel Converts Class C Shares to Common Stock | equities.com - 0 views

editorial.equities.com/...class-c-shares-to-common-stock

equities.com RepliCel REPCF life sciences Class C stock common stock hair regeneration Phase IIb clinical trials baldness cure pattern baldness female pattern baldness

shared by Equities Group on 01 Dec 11 - No Cached
  • Equities Group on 01 Dec 11
     
    RepliCel, which is currently testing their groundbreaking procedure for treating baldness, has converted 13 million shares of Class C stock into common stock.
Equities Group

RepliCel's Update Shows Clinical Trial is on Track - 0 views

editorial.equities.com/...licels-clinical-trial-on-track

"Equities.com" "RepliCel" "Clinical "REPCF" "RepliCel Life Sciences" "first-in-man clinical trials" "treatment" "hair loss" "alopecia" "injections" "verum" "placebo injections" "scalp" "technology" "regeneration" "hair" "dermal sheath cup cells" follicles

shared by Equities Group on 01 Feb 12 - No Cached
  • Equities Group on 01 Feb 12
     
    With its six-month post injection follow-up period for its key clinical trial nearing completion, RepliCel provides an update on its innovative hair loss treatment.
Equities Group

Interview with Dr. Rolf Hoffmann, RepliCel's Chief Medical Officer | equities.com - 0 views

editorial.equities.com/...officer-replicel-life-sciences

RepliCel equities.com REPCF biotechnology hair-loss alopecia hair regeneration hair cup sheath cup cells follicles Rogaine Propecia

shared by Equities Group on 22 Nov 11 - No Cached
  • Equities Group on 22 Nov 11
     
    Leading hair biology scientist Rolf Hoffmann discusses in cell-based hair loss treatments and the critical steps RepliCel Life Sciences is taking to ensure that it is successful.
1 - 3 of 3
Showing 20▼ items per page